These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 27563246

  • 1. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV, O'Callaghan JM, Handa A.
    Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
    Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP, ENGAGE AF-TIMI 48 Investigators.
    Circulation; 2017 Mar 28; 135(13):1273-1275. PubMed ID: 28209729
    [No Abstract] [Full Text] [Related]

  • 9. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Lanz HJ, Mont L, Morillo CA, Smolnik R, Yin OQP, Kautzner J.
    Clin Cardiol; 2018 Apr 28; 41(4):440-449. PubMed ID: 29663464
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
    AlHajri L, Jabbari S, AlEmad H, AlMahri K, AlMahri M, AlKitbi N.
    J Cardiovasc Pharmacol Ther; 2017 May 28; 22(3):230-238. PubMed ID: 27811198
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.
    Am Heart J; 2010 Oct 28; 160(4):635-41. PubMed ID: 20934556
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
    Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M, Duris T, Juul-Möller S, Voitk J, Trevisan M, Nordio F, Antman EM, Giugliano RP.
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul 01; 6(3):167-175. PubMed ID: 31687762
    [Abstract] [Full Text] [Related]

  • 18. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
    Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S.
    Thromb Haemost; 2010 Sep 01; 104(3):633-41. PubMed ID: 20694273
    [Abstract] [Full Text] [Related]

  • 19. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
    Aspromonte N, Colivicchi F.
    Expert Opin Drug Metab Toxicol; 2017 Jan 01; 13(1):113-122. PubMed ID: 27819149
    [Abstract] [Full Text] [Related]

  • 20. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF, Ganetsky V, Spinler SA.
    Clin Ther; 2013 Jan 01; 35(1):4-27. PubMed ID: 23328267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.